Devita, Hellman, and Rosenberg's Cancer

LWBK1006-09 LWW-Govindan-Review December 12, 2011 18:51

108 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 9.16. What is the major limitation of using antibody-based therapies against

tumors that overexpress CEA?

A. Delivery of the antibody to the tumor

B. Penetration of the tumor tissue

C. Invasion of normal CEA-expressing tissue

D. Stabilization of the antibody

Question 9.17. Which of the following most correctly defines immunoediting?

A. Observation by the immune system for development of outgrowth of

tumors

B. Selective pressure by immune systems leads to outgrowth of mutated

tumor variants

C. Development of mechanisms by the tumor to prevent recognition by

the immune system

D. Use of cytokine release to inhibit response by T cells

Question 9.18. In patients with renal cell carcinoma, which of the following factors pre-

dict response to high-dose interleukin-2 (IL-2) therapy?

A. Presence of bone metastases

B. Relapse 3 months after nephrectomy

C. Clear cell histology

D. All of the above

Question 9.19. Which of the following gene products is frequently overexpressed in

melanoma?

A. PRAME

B. CDK4

C. MART-1

D. FGF5

Question 9.20. Which of the following is correct regarding high-dose IL-2 therapy in

patients with renal cell carcinoma and melanoma?

A. Response durations can be sustained with curative potential

B. High-dose IL-2 therapy is associated with minimal toxicity

C. Overall response rate for IL-2 in renal cell carcinoma is 70%

D. All of the above

Question 9.21. Which of the following is NOT an immune-mediated adverse reaction of

ipilimumab?

A. Enterocolitis

B. Dermatitis

C. Hyperthyroidism

D. Peripheral neuropathy